NIKKEI 225
38,385.73 +29.67 (+0.08%) HANG SENG
19,073.71 -41.35 (-0.22%) CRUDE OIL
78.70 +0.68 (+0.87%) GOLD FUTURES
2,390.50 +30.60 (+1.30%) DOW
39,823.33 +265.22 (+0.67%) Bitcoin GBP
51,616.62 +3,222.13 (+6.66%)
Celularity Inc. (CELU)
| Previous close | 3.6400 |
| Open | 3.7200 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 3.1810 - 3.8000 |
| 52-week range | 1.5900 - 8.9000 |
| Volume | |
| Avg. volume | 73,457 |
| Market cap | 71.666M |
| Beta (5Y monthly) | 0.43 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -10.3000 |
| Earnings date | 17 May 2024 - 01 Jun 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Celularity Data Published in Journal for ImmunoTherapy of Cancer Reveals Benefits of Placental Circulating T Cells for CAR-T Therapy
Placental T Cells Demonstrated Greater Persistence, Resistance to Exhaustion and Efficacy Compared To Peripheral Blood Mononuclear CellsFLORHAM PARK, N.J., May 14, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ: CELU) (“Celularity”), a regenerative and cellular medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced today that the Journal for ImmunoTherapy of Cancer, a peer-reviewed online journal of the Society for Immunotherapy of
- GlobeNewswire
Celularity Inc. to Host Investor and Analyst Research & Development Day
Event Will Be Hosted On-site and Aired Virtually Highlighting Research, Clinical and Commercial ProgressFLORHAM PARK, N.J., April 22, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ: CELU) (“Celularity”), a regenerative and cellular medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced today it will host an on-site and virtual Investor and Analyst Research & Development (R&D) Day. The Investor and R&D Day, scheduled for Tuesday, May
- GlobeNewswire
Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing
FLORHAM PARK, N.J., April 19, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ: CELU) (the “Company”), a regenerative medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced today that on April 17, 2024, the Company received notification from the Listing Qualifications department of the Nasdaq Stock Market LLC (“Nasdaq”) stating that because the Company has not yet filed its Annual Report on Form 10-K for the year ended December 31, 20
